Koers Fennec Pharmaceuticals Inc. Nasdaq
Aandelen
CA31447P1009
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 50 mln. 46,76 mln. | Omzet 2025 * | 71,15 mln. 66,54 mln. | Marktkapitalisatie | 250 mln. 233 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 5 mln. 4,68 mln. | Nettowinst (verlies) 2025 * | 26 mln. 24,32 mln. | EV/omzet 2024 * | 4,99 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,51 x |
K/w-verhouding 2024 * |
44,2
x | K/w-verhouding 2025 * |
9,89
x | Werknemers | 29 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 84,71% |
Recentste transcriptie over Fennec Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07-07-09 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07-07-09 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 25-08-11 |
Khalid Islam
CHM | Chairman | 67 | 25-04-14 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07-07-09 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,71 mld. | |
+1,69% | 22,02 mld. | |
-17,37% | 20,9 mld. | |
-9,30% | 17,85 mld. | |
-41,01% | 16,21 mld. | |
-14,85% | 15,52 mld. | |
+3,21% | 13,86 mld. | |
+33,54% | 12,04 mld. |